Application of albiglutide to medicines for treating and preventing diabetic mellitus complicated with cerebral infarction
A technology of albiglutide and cerebral infarction, which is applied in the application field of albiglutide in the treatment and prevention of diabetes combined with cerebral infarction, and can solve the problems of patients with backward treatment methods and failure to effectively control blood sugar
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0011] Example 1 The therapeutic effect of albiglutide on patients with diabetes mellitus complicated with cerebral infarction
[0012] Experimental objects and grouping: 360 cases of cerebral infarction patients within 48 hours of onset were randomly selected clinically, including 240 cases in the treatment group and 120 cases in the control group. In all cases, oral hypoglycemic drugs were used according to the condition, so that the fasting blood sugar was controlled at 6-8mmol / L, blood pressure was stabilized, and small doses of dehydrating agents, calcium antagonists (nimodipine), and platelet inhibitors (small doses of aspirin) were used. Anti-infection and other symptomatic treatment. Treatment group: subcutaneous injection of Albiglutide injection 30mg, once a day, 28 days as a course of treatment; control group: subcutaneous injection of the same amount of normal saline, once a day, 28 days as a course of treatment. Those with serious condition will take 2 courses of...
Embodiment 2
[0019] Example 2 Treatment of Albiglutide on Diabetes with Cerebral Infarction
[0020] 80 patients were randomly divided into two groups according to the random table generated by computer SPSS software. The treatment group consisted of 40 cases, 21 males and 19 females; aged 57.5-86.5 years old; neurological deficit score 15-39 points, with an average of (23.1±7.8) points. The control group consisted of 40 cases, 23 males and 17 females; aged 54.5-85.5 years; neurological deficit score l4-38 points, average (22.7 ± 6.6) points. There was no significant difference in gender, age, and neurological deficit scores between the two groups through statistical analysis (P>0.05), and they were comparable. Both groups were given routine treatment (OADs, dehydration drugs and supportive therapy, etc.). On this basis, the treatment group was given subcutaneous injection of albiglutide 30 mg, once a day, for 28 consecutive days; the control group was given the same amount of normal sal...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 

